International Journal of Gynecological Cancer

Endocrine Treatment and Prevention of Breast and Gynecological Cancers Vth International Symposium of the Flemish Gynecological Oncology Group, January 26-28, 2006
pp. 479-491(13)
Authors: NEVEN,; VERGOTE,; AMANT,; BERTELOOT,; deJONGE,; DE ROP,; DE SUTTER,; MAKAR,; VAN GINDERACHTER,

ANTHROPOMETRY, PHYSICAL ACTIVITY, AND ENDOMETRIAL CANCER RISK: RESULTS FROM THE NETHERLANDS COHORT STUDY
pp. 492-492(1)
Authors: Schouten,; Goldbohm,; van den Brandt,

ANDROGENS AND BREAST CANCER
pp. 493-493(1)
Author: Franco,

Exogenous steroids for menopausal symptoms and breast/endometrial cancer risk
pp. 494-496(3)
Authors: MOURITS,; DE BOCK,

Insulin-like growth factor-1 genotype predicts breast volume after pregnancy and hormonal contraception and is associated with circulating insulin-like growth factor-1 levels: implications for risk of early-onset breast cancer in young women from hereditary breast cancer families
pp. 497-497(1)
Authors: Jernström,; Sandberg,; Bågeman,; Borg,; Olsson,

An update on breast cancer prevention trials
pp. 498-501(4)
Authors: WICKERHAM,; FOURCHOTTE,

An update on raloxifene
pp. 502-503(2)
Author: Draper,

Not all selective estrogen response modulators are created equal: update on lasofoxifene
pp. 504-504(1)
Author: Goldstein,

Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view
pp. 505-510(6)
Authors: NEVEN,; PARIDAENS,; AMANT,; WILDIERS,; BERTELOOT,; LEUNEN,; SMEETS,; WELTENS,; van denBOGAERT,; vanLIMBERGEN,; CHRISTIAENS,; VERGOTE,

An update on ovarian suppression/ablation
pp. 511-514(4)
Author: JAKESZ,

Endometrial safety of third generation aromatase inhibitors versus tamoxifen in breast cancer patients
pp. 515-517(3)
Authors: MORALES,; TIMMERMAN,; NEVEN,; PARIDAENS,

Bone safety of aromatase inhibitors versus tamoxifen
pp. 518-520(3)
Authors: LØNNING,

Is fulvestrant (“Faslodex”) just another selective estrogen receptor modulator?
pp. 521-523(3)
Author: HOWELL,

Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant
pp. 524-526(3)
Authors: VERGOTE,; AMANT,; LEUNEN,; VAN GORP,; BERTELOOT,; NEVEN,

Endometrial cancer: predictors of response and preferred endocrine therapy
pp. 527-528(2)
Authors: AMANT,; LEUNEN,; NEVEN,; BERTELOOT,; VERGOTE,

How to measure and report the estrogen (and progesterone) receptor in breast cancer
pp. 529-532(4)
Authors: VERMEULEN,; VAN LAERE,; DIRIX,

Better predictive factors in endocrine-responsive breast cancer than the estrogen receptor itself
pp. 533-537(5)
Authors: CARDOSO,; DAL LAGO,; BRAGA,

Gene expression profiling of treatment resistance: hype or hope for therapeutic target identification
pp. 538-542(5)
Authors: HELLEMAN,; JANSEN,; BERNS,

Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists
pp. 543-548(6)
Author: JOHNSTON,

Is cancer risk related to genes for steroid receptors and estrogen metabolism?
pp. 549-551(3)
Author: LEGIUS,

Association between the CHEK2*1100delC germ line mutation and estrogen receptor status
pp. 552-555(4)
Authors: deBOCK,; MOURITS,; SCHUTTE,; KROL-WARMERDAM,; SEYNAEVE,; BLOM,; BREKELMANS,; MEIJERS-HEIJBOER,; vanASPEREN,; CORNELISSE,; DEVILEE,; TOLLENAAR,; KLIJN,

Interleukin-1α protein secretion in breast cancer is associated with poor differentiation and estrogen receptorα negativity
pp. 556-559(4)
Authors: SINGER,; HUDELIST,; GSCHWANTLER-KAULICH,; FINK-RETTER,; MUELLER,; WALTER,; CZERWENKA,; KUBISTA,

Effects of 17β-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messengerRNA in breast cancer cells
pp. 560-563(4)
Authors: MIRKIN,; WONG,; ARCHER,

An estrogen receptor α-dependent regulation of estrogen receptor-related receptor α in the proliferation of endometrial carcinoma cells
pp. 564-568(5)
Authors: SUN,; GAO,; WEI,; MUSTEA,; WANG,; KÖNSGEN,; LICHTENEGGER,; SEHOULI,

Growth patterns and the risk of breast cancer in women
pp. 569-575(7)
Authors: AHLGREN,; MELBYE,; WOHLFAHRT,; SØRENSEN,

Cost-effectiveness of anastrozole compared to tamoxifen in hormone receptor-positive early breast cancer. Analysis based on the ATAC trial
pp. 576-578(3)
Authors: MOEREMANS,; ANNEMANS,

Oral Abstracts
pp. 579-588(10)

Poster Presentations
pp. 589-598(10)